144 related articles for article (PubMed ID: 26356319)
1. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group.
Mauz-Körholz C; Lange T; Hasenclever D; Burkhardt B; Feller AC; Dörffel W; Kluge R; Vordermark D; Körholz D
Klin Padiatr; 2015 Nov; 227(6-7):314-21. PubMed ID: 26356319
[TBL] [Abstract][Full Text] [Related]
2. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].
Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J
Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647
[TBL] [Abstract][Full Text] [Related]
3. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
4. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
Olszewski AJ; Shrestha R; Cook NM
Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
6. The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma.
Lüders H; Rühl U; Marciniak H; Haerting J; Claviez A; Mann G; Schellong G; Wickmann L; Dörffel W
Eur J Cancer; 2014 Jan; 50(2):425-33. PubMed ID: 24157256
[TBL] [Abstract][Full Text] [Related]
7. Modern management of lymphocyte-predominant Hodgkin lymphoma.
Xing KH; Savage KJ
Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605
[TBL] [Abstract][Full Text] [Related]
8. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
Fanale M
Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
[TBL] [Abstract][Full Text] [Related]
10. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site.
Cotta CV; Coleman JF; Li S; Hsi ED
Histopathology; 2011 Dec; 59(6):1194-203. PubMed ID: 22175899
[TBL] [Abstract][Full Text] [Related]
11. Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.
Sidda A; Naleid NK; Manu G; Graffeo V; Jamil MO
J Investig Med High Impact Case Rep; 2022; 10():23247096221111767. PubMed ID: 35861500
[TBL] [Abstract][Full Text] [Related]
12. Acute psychosis in an adolescent girl during treatment for advanced nodular lymphocyte-predominant Hodgkin's lymphom.
Pinkwart C; Stiefel M; Mauz-Körholz C; Körholz D
Klin Padiatr; 2011 Nov; 223(6):370-1. PubMed ID: 22052634
[TBL] [Abstract][Full Text] [Related]
13. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
14. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
Gloghini A; Bosco A; Ponzoni M; Spina M; Carbone A
Expert Rev Hematol; 2015 Apr; 8(2):217-23. PubMed ID: 25487651
[TBL] [Abstract][Full Text] [Related]
15. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.
Molin D; Linderoth J; Wahlin BE
Br J Haematol; 2017 May; 177(3):449-456. PubMed ID: 28233899
[TBL] [Abstract][Full Text] [Related]
16. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report.
Shankar A; Hall GW; Gorde-Grosjean S; Hasenclever D; Leblanc T; Hayward J; Lambilliotte A; Daw S; Perel Y; McCarthy K; Lejars O; Coulomb A; Oberlin WO; Wallace WH; Landman-Parker J
Eur J Cancer; 2012 Jul; 48(11):1700-6. PubMed ID: 22093944
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
David JA; Huang JZ
Am J Clin Pathol; 2016 Jan; 145(1):107-15. PubMed ID: 26712878
[TBL] [Abstract][Full Text] [Related]
19. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
Prasad M; Narula G; Chinnaswamy G; Arora B; Shet T; Panjwani P; Sengar M; Laskar S; Khanna N; Banavali S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
